health partners glp 1 coverage Patients Face New Barriers for GLP-1 Drugs The GLP-1 Access Gap: Mapping

This phenomenon has been observed with other diabetes treatments as well

The drugmakers that make Zepbound and Wegovy sell the medicines at a discount to people who pay out of pocket instead of using insurance

Trademark Notice

Novo Nordisk's semaglutide beats its counterpart liraglutide to become the next generation of weight loss innovation, and then Eli Lilly's GLP-1R/GIPR dual-target agonist tirzepatide achieves a 22.5% weight loss, surpassing semaglutide's weight loss history

Thirty-eight percent cited the costs associated with GLP-1s as a potential barrier to providing coverage

For 40+ years, my work and that of others supported the view that addiction is a disorder of maladaptive dopaminergic learning